Clinical Trial Update: Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating optimized neoadjuvant therapy for HER2-positive early-stage breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: HER2-positive Early-stage Breast Cancer | Phase 2 | Status: RECRUITING